Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02AAO
|
||||
| Former ID |
DIB014475
|
||||
| Drug Name |
AZD-4877
|
||||
| Synonyms |
Anticancer therapeutic (solid tumors), AstraZeneca
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] | Phase 2 | [1], [2] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H33N5O2S
|
||||
| InChI |
InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3
|
||||
| InChIKey |
SMFXSYMLJDHGIE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Kinesin-like protein KIF11 | Target Info | Inhibitor | [3] | |
| Reactome | MHC class II antigen presentation | ||||
| Kinesins | |||||
| WikiPathways | MHC class II antigen presentation | ||||
| Kinesins | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00661609) A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7708). | ||||
| REF 3 | Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.